Results 221 to 230 of about 1,577,460 (391)

Out-of-field neutron radiation from clinical proton, helium, carbon, and oxygen ion beams. [PDF]

Med Phys
Bolzonella M, Caresana M, Cirillo A, Martí-Climent JM, Martínez-Francés E, Mooshammer C, Schmidt S, Brons S, Silari M, Stengl C, Stolarczyk L, Vedelago J.   +11 more
europepmc   +1 more source

A driftless gas proportional scintillation counter for muonic hydrogen X-ray spectroscopy under strong magnetic fields [PDF]

, 2001
J.F.C.A. Veloso, J.M.F. dos Santos, C.A.N. Conde, F. Mulhauser, P. Knowles, C. Donche-Gay, O. Huot, D. Taqqu, F. Kottmann   +8 more
openalex   +1 more source

BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach, Nunziata Maio, Russell J. Butterfield, A. Reghan Foley, Sarah Silverstein, Yan Li, Katherine Chao, Tanya J. Lehky, Abigail Potticary, Tracey A. Rouault, Sandra Donkervoort, Carsten G. Bönnemann   +11 more
wiley   +1 more source

Development of portable gas proportional scintillation counters for x‐ray spectrometry [PDF]

, 2001
J.M.F. dos Santos, J. A. M. Lopes, J.F.C.A. Veloso, P.C.P.S. Simões, T.H.V.T. Dias, F.P. Santos, P.J.B.M. Rachinhas, L. F. Requicha Ferreira, C.A.N. Conde   +8 more
openalex   +1 more source

Glial Fibrillary Acidic Protein Astrocytopathy Based on a Two‐Center Chinese Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glial fibrillary acidic protein astrocytopathy (GFAP‐A) is a recently defined nosological form belonging to the class of autoimmune inflammatory disorders affecting the central nervous system (CNS). Here, we report the clinical and MRI characteristics, treatment, and prognosis of a GFAP‐A cohort from two centers in China.
Ti Wu, Hao Zhang, Chao Gao, Qiuhua Yu, Moli Fan, Lin‐Jie Zhang, Haipeng Zhang, Hengri Cong, Yuzhen Wei, Chotima Böttcher, Alexej Verkhratsky, Friedemann Paul, Fu‐Dong Shi, Tian Song   +13 more
wiley   +1 more source

A multiwire proportional counter for XAS fluorescence experiments [PDF]

, 2001
Raúl A. Barrea, E. Tamura, H. Tolentino
openalex   +1 more source

Clinical Characteristics of Parkinsonism in HTLV‐1‐Associated Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Human T‐lymphotropic virus type 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the classic neurological manifestation of HTLV‐1 infection; however, this virus has also been associated with other neurological disorders. Concurrent parkinsonism is relatively rare and presents diagnostic challenges.
Mika Dozono, Satoshi Nozuma, Shota Hirakata, Takashi Yoshida, Daisuke Kodama, Masakazu Tanaka, Eiji Matsuura, Ryuji Kubota, Hiroshi Takashima   +8 more
wiley   +1 more source

Numerical analysis of flow configuration and channel design for thermoelectric OTEC systems. [PDF]

Sci Rep
Wu CI, Tseng WL, Wang BX.
europepmc   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
wiley   +1 more source

Incidence of non-cardia gastric cancer among commercially-insured individuals aged 18-64 with chronic atrophic gastritis. [PDF]

PLoS One
Huang RJ, Balasubramanian V, Shum MV, Ji HP, Hwang JH.   +4 more
europepmc   +1 more source